Immuno-inflammatory, oxidative and nitrosative stress, and neuroprogressive pathways in the etiology, course and treatment of schizophrenia

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 42, Issue , 2013, Pages 1-4

  Anderson, George ^a   Berk, Michael ^b,c,d   Dodd, Seetal ^b   Bechter, Karl ^e   Altamura, A Carlo ^f   Dell'Osso, Bernardo ^f   Kanba, Shigenobu ^g   Monji, Akira ^h   Fatemi, S Hossein ⁱ   Buckley, Peter ^j   Debnath, Monojit ^k   Das, U N ^l   Meyer, Urs ^m   Müller, Norbert ⁿ   Kanchanatawan, Buranee ^o   Maes, Michael ^b,o,p,q  

^a CRC   (United Kingdom)

^b DEAKIN UNIVERSITY   (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

^d UNIVERSITY OF MELBOURNE   (Australia)

^e UNIVERSITY OF ULM   (Germany)

^f UNIVERSITY OF MILAN   (Italy)

^g KYUSHU UNIVERSITY   (Japan)

^h SAGA UNIVERSITY   (Japan)

ⁱ UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^j MEDICAL COLLEGE OF GEORGIA   (United States)

^k NATIONAL INSTITUTE OF MENTAL HEALTH AND NEUROSCIENCES   (India)

^l UND LIFE SCIENCES   (United States)

^m ETH ZURICH   (Switzerland)

ⁿ UNIVERSITY OF MUNICH   (Germany)

^o CHULALONGKORN UNIVERSITY   (Thailand)

^p Piyavate Hospital   (Thailand)

^q International PNI Reference Center   (Netherlands)

more..

Author keywords

Cytokines; Inflammation; Neuroprogression; Oxidative and nitrosative stress; Schizophrenia; Tryptophan catabolites

Indexed keywords

ANTIINFLAMMATORY AGENT; LEPTIN; NEUROLEPTIC AGENT; POLYUNSATURATED FATTY ACID; VITAMIN D;

APOPTOSIS; CELL ACTIVATION; DISEASE COURSE; DISEASE PREDISPOSITION; EDITORIAL; FETUS HYPOXIA; GENE EXPRESSION; GENE FUNCTION; GENE INTERACTION; GENOTYPE ENVIRONMENT INTERACTION; HUMAN; IMMUNE RESPONSE; IMMUNOMODULATION; INTRAUTERINE INFECTION; MAJOR HISTOCOMPATIBILITY COMPLEX RESTRICTION; MICROGLIA; NERVE DEGENERATION; NERVOUS SYSTEM INFLAMMATION; NEUROPATHOLOGY; NITROSATIVE STRESS; NONHUMAN; OXIDATIVE STRESS; RISK ASSESSMENT; SCHIZOPHRENIA; VIRUS INFECTION; VITAMIN BLOOD LEVEL;

DISEASE PROGRESSION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATION; NITROSATION; OXIDATION-REDUCTION; OXIDATIVE STRESS; SCHIZOPHRENIA; TREATMENT OUTCOME;

EID: 84873526090     PISSN: 02785846     EISSN: 18784216     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2012.10.008     Document Type: Editorial

References (42)

1. Altamura A.C., Pozzoll S., Fiorentini A. Dell'Osso B. Neurodevelopment and inflammatory patterns in schizophrenia in relation to pathophysiology. Prog Neuropsychopharmacol Biol Psychiatry 2013, 42:63-70. (this issue).
2. Anderson G., Maes M. Schizophrenia: linking prenatal infection to cytokines, the tryptophan catabolite (TRYCAT) pathway, NMDA receptor hypofunction, neurodevelopment and neuroprogression. Prog Neuropsychopharmacol Biol Psychiatry 2013, 42:5-19. (this issue).
3. Anderson G., Maes M., Berk M. Schizophrenia is primed for an increased expression of depression through activation of immuno-inflammatory, oxidative and nitrosative stress, and tryptophan catabolite pathways. Prog Neuropsychopharmacol Biol Psychiatry 2013, 42:101-114. (this issue).
4. Battersby A.J., Kampmann B., Burl S. Vitamin D in early childhood and the effect on immunity to Mycobacterium tuberculosis. Clin Dev Immunol 2012, 2012:430972.
5. Bechter K. Updating the mild encephalitis hypothesis of schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2013, 42:71-91. (this issue).
6. Berk M., Conus P., Kapczinski F., Andreazza A.C., Yücel M., Wood S.J., et al. From neuroprogression to neuroprotection: implications for clinical care. Med J Aust 2010, 193(4 Suppl.):S36-S40. (Aug 16).
7. Beumer W., Gibney S.M., Drexhage R.C., Pont-Lezica L., Doorduin J., Klein H.C., et al. The immune theory of psychiatric diseases: a key role for activated microglia and circulating monocytes. J Leukoc Biol 2012, 92(5):959-975. (Nov).
8. Brown A.S., Derkits E.J. Prenatal infection and schizophrenia: a review of epidemiologic and translational studies. Am J Psychiatry 2010, 167:261-280.
9. Brown A.S., Begg M.D., Gravenstein S., Schaefer C.A., Wyatt R.J., Bresnahan M., et al. Serologic evidence of prenatal influenza in the etiology of schizophrenia. Arch Gen Psychiatry 2004, 61:774-780.
10. Cannon T.D., van Erp T.G., Rosso I.M., Huttunen M., Lönnqvist J., Pirkola T., et al. Fetal hypoxia and structural brain abnormalities in schizophrenic patients, their siblings, and controls. Arch Gen Psychiatry 2002, 59:35-41.
11. Chigusa Y., Tatsumi K., Kondoh E., Fujita K., Nishimura F., Mogami H., et al. Decreased lectin-like oxidized LDL receptor 1 (LOX-1) and low Nrf2 activation in placenta are involved in preeclampsia. J Clin Endocrinol Metab 2012, 97(10):E1862-E1870. (Oct).
12. Cotton S.M., Lambert M., Schimmelmann B.G., Mackinnon A., Gleeson J.F., Berk M., et al. Depressive symptoms in first episode schizophrenia spectrum disorder. Schizophr Res 2012, 134(1):20-26. (Jan).
13. Das U. Polyunsaturated fatty acids and their metabolites in the pathobiology of schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2013, 42:122-134. (this issue).
14. Debnath M., Cannon D.M., Venkatasubramanian G. Variation in the major histocompatibility complex [MHC] gene family in schizophrenia: associations and functional implications. Prog Neuropsychopharmacol Biol Psychiatry 2013, 42:49-62. (this issue).
15. Dodd S., Maes M., Anderson G., Dean O., Moylan S., Berk M. Putative neuroprotective agents in neuropsychiatric disorders. Prog Neuropsychopharmacol Biol Psychiatry 2013, 42:135-145. (this issue).
16. Fatemi S.H., Folsom T.D. The neurodevelopmental hypothesis of schizophrenia, revisited. Schizophr Bull 2009, 35(3):528-554.
17. Fernando M.M.A., Stevens C.R., Walsh E.C., DeJager P.L., Goyette P., Plenge R.M., et al. Defining the role of the MHC in autoimmunity: a review and pooled analysis. PLoS Genet 2008, 4:e1000024.
18. Fillman SG, Cloonan N, Catts VS, Miller LC, Wong J, McCrossin T. Increased inflammatory markers identified in the dorsolateral prefrontal cortex of individuals with schizophrenia. Mol Psychiatry in press.
19. Ganz T., Nemeth E. Iron sequestration and anemia of inflammation. Semin Hematol 2009, 46:387-393.
20. Gozdzik-Zelazny A., Borecki L., Pokorski M. Depressive symptoms in schizophrenic patients. Eur J Med Res 2011, 16(12):549-552.
21. Heckers S. Diagnostic criteria for schizoaffective disorder. Expert Rev Neurother 2012, 12(1):1-3.
22. Kendell R.E., Juszczak E., Cole S.K. Obstetric complications and schizophrenia: a case control study based on standardised obstetric records. Br J Psychiatry 1996, 168:55-61.
23. Khandaker G.M., Zimbron J., Lewis G., Jones P.B. Prenatal maternal infection, neurodevelopment and adult schizophrenia: a systematic review of population based studies. Psychol Med 2012, 1-19. (Apr 16).
24. Kneeland R.E., Fatemi S.H. Viral infection, inflammation and schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2013, 42:35-48. (this issue).
25. Krstic D., Madhusudan A., Doehner J., Vogel P., Notter T., Imhof C., et al. Systemic immune challenges trigger and drive Alzheimer-like neuropathology in mice. J Neuroinflammation 2012, 9(1):151.
26. Laugeray A., Launay J.M., Callebert J., Surget A., Belzung C., Barone P.R. Peripheral and cerebral metabolic abnormalities of the tryptophan-kynurenine pathway in a murine model of major depression. Behav Brain Res 2010, 210(1):84-91.
27. Laugeray A., Launay J.M., Callebert J., Surget A., Belzung C., Barone P.R. Evidence for a key role of the peripheral kynurenine pathway in the modulation of anxiety- and depression-like behaviours in mice: focus on individual differences. Pharmacol Biochem Behav 2011, 98:161-168.
28. Liu N.Q., Kaplan A.T., Lagishetty V., Ouyang Y.B., Ouyang Y., Simmons C.F., et al. Vitamin D and the regulation of placental inflammation. J Immunol 2011, 186:5968-5974.
29. McGrath J., Eyles D., Mowry B., Yolken R., Buka S. Low maternal vitamin D as a risk factor for schizophrenia: a pilot study using banked sera. Schizophr Res 2003, 63(1-2):73-78.
30. Meyer U. Developmental neuroinflammation and schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2013, 42:20-34. (this issue).
31. Meyer U., Nyffeler M., Engler A., Urwyler A., Schedlowski M., Knuesel I., et al. The time of prenatal immune challenge determines the specificity of inflammation-mediated brain and behavioral pathology. J Neurosci 2006, 26(18):4752-4762.
32. Miller B.J., Culpepper N., Rapaport M.H., Buckley P. Prenatal inflammation and neurodevelopment in schizophrenia: a review of human studies. Prog Neuropsychopharmacol Biol Psychiatry 2013, 42:92-100. (this issue).
33. Monji A., Kato T.A., Mizoguchi Y., Horikawa H., Seki Y., Kasai M., et al. Neuroinflammation in schizophrenia especially focused on the role of microglia. Prog Neuropsychopharmacol Biol Psychiatry 2013, 42:115-121. (this issue).
34. Müller N., Myint A.-M., Krause D., Weidinger E., Schwarz M.J. Anti-inflammatory treatment in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2013, 42:146-153. (this issue).
35. Nicodemus K.K., Marenco S., Batten A.J., Vakkalanka R., Egan M.F., Straub R.E., et al. Serious obstetric complications interact with hypoxia-regulated/vascular-expression genes to influence schizophrenia risk. Mol Psychiatry 2008, 13:873-877.
36. Pasco J.A., Jacka F.N., Williams L.J., Henry M.J., Nicholson G.C., Kotowicz M.A., et al. Leptin in depressed women: cross-sectional and longitudinal data from an epidemiologic study. J Affect Disord 2008, 107(1-3):221-225.
37. Prasad A.S. Zinc: role in immunity, oxidative stress and chronic inflammation. Curr Opin Clin Nutr Metab Care 2009, 12:646-652.
38. Schmidt-Kastner R., Van Os J., Steinbusch H.M.W., Schmitz C. Gene regulation by hypoxia and the neurodevelopmental origin of schizophrenia. Schizophr Res 2006, 84:253-271.
39. Shibakawa Y.S., Sasaki Y., Goshima Y., Echigo N., Kamiya Y., Kurahashi K., et al. Effects of ketamine and propofol on inflammatory responses of primary glial cell cultures stimulated with lipopolysaccharide. Br J Anaesth 2005, 95(6):803-810.
40. Smith R.S., Maes M. The macrophage-T-lymphocyte theory of schizophrenia: additional evidence. Med Hypotheses 1995, 45(2):135-141.
41. Wood S.J., Yücel M., Pantelis C., Berk M. Neurobiology of schizophrenia spectrum disorders: the role of oxidative stress. Ann Acad Med Singapore 2009, 38(5):396-401.
42. Zammit S., Odd D., Horwood J., Thompson A., Thomas K., Menezes P., et al. Investigating whether adverse prenatal and perinatal events are associated with non-clinical psychotic symptoms at age 12 years in the ALSPAC birth cohort. Psychol Med 2009, 39:1457-1467.